Table of Contents
Overview
New York, NY – July 21, 2025 – The Global Endoscopic Ultrasound Needles Market Size is expected to be worth around USD 267.7 Million by 2033, from USD 158.2 Million in 2023, growing at a CAGR of 5.4% during the forecast period from 2024 to 2033.
The global Endoscopic Ultrasound (EUS) Needles market is experiencing notable growth, driven by rising demand for minimally invasive diagnostic and therapeutic procedures. EUS needles are essential tools in gastroenterology, particularly for obtaining tissue samples from the pancreas, lymph nodes, and other structures located adjacent to the gastrointestinal tract. These devices enhance diagnostic accuracy for conditions such as pancreatic cancer, gastrointestinal tumors, and cystic lesions.
Growing preference for fine-needle aspiration (FNA) and fine-needle biopsy (FNB) techniques, supported by advancements in needle design such as improved tip sharpness, echogenic marking, and enhanced maneuverability has increased the adoption rate in clinical settings. The demand is also bolstered by the increasing prevalence of gastrointestinal cancers and the expansion of endoscopic ultrasound procedures in both developed and emerging markets.
Furthermore, healthcare providers are adopting EUS-guided interventions for therapeutic purposes, including pseudocyst drainage and targeted drug delivery, thereby expanding the utility of these needles beyond diagnostics. Regulatory approvals for novel needle types and strategic collaborations among medical device companies are expected to further accelerate market penetration.
With ongoing innovations and broader clinical applications, the EUS needles market is projected to witness steady growth in the coming years, positioning itself as a key component in advanced endoscopic procedures across global healthcare systems.
Key Takeaways
- In 2023, the Endoscopic Ultrasound Needles market generated a revenue of USD 158.2 million and is projected to reach USD 267.7 million by 2033, expanding at a CAGR of 5.4% over the forecast period.
- By product type, biopsy needles accounted for the largest share in 2023, holding 54.1% of the total market, surpassing aspiration needles.
- In terms of application, bronchial EUS needles dominated with a 57.2% share, compared to enteral EUS needles.
- Among end users, hospitals emerged as the leading segment, contributing to 62.3% of total revenue in 2023, driven by high procedural volumes and availability of advanced imaging infrastructure.
- Regionally, North America held the largest market share of 41.1% in 2023, attributed to established healthcare systems, rising adoption of minimally invasive procedures, and supportive reimbursement policies.
Segmentation Analysis
- Product Analysis: In 2023, the biopsy needles segment dominated the market with a 54.1% share, driven by its increasing application in diagnosing cancers and non-pancreatic conditions such as lymphoma and autoimmune pancreatitis. The growing burden of pancreatic cancer, fueled by smoking, obesity, and diabetes as noted by the American Cancer Society has intensified the demand for precise diagnostic tools like biopsy needles. Their role in early cancer detection is expected to sustain segment growth throughout the forecast period.
- Application Analysis: Bronchial EUS needles accounted for a 57.2% market share in 2023 due to their rising use in diagnosing and staging lung cancer. Technological advancements such as enhanced needle echogenicity and design are improving accuracy and safety in bronchial tissue sampling. Increasing incidence of lung cancer, coupled with the demand for minimally invasive diagnostic methods, is supporting segment growth. Their expanding role in diagnosing mediastinal lesions and lymph nodes further strengthens market penetration.
- End-user Analysis: Hospitals emerged as the leading end-user segment in 2023, capturing 62.3% of revenue, owing to increased use of endoscopic ultrasound for cancer diagnosis and staging. Rising demand for outpatient and minimally invasive procedures, along with investments in healthcare infrastructure, has fueled adoption. Hospitals remain key centers for high-volume EUS needle procedures, supported by trained personnel and advanced equipment. Greater awareness among patients and healthcare providers continues to drive procedural growth within this segment.
Market Segments
By Product
- Biopsy Needles
- Aspiration Needles
By Application
- Enteral EUS Needles
- Bronchial EUS Needles
By End-user
- Hospitals
- Ambulatory Surgery Centers
- Specialty Clinics
Regional Analysis
North America led the global Endoscopic Ultrasound Needles market in 2023, accounting for the highest revenue share of 41.1%. This dominance is attributed to the region’s well-established healthcare infrastructure, advanced diagnostic technologies, and high prevalence of cancer.
Increased adoption of endoscopic ultrasound in oncology, gastroenterology, and pulmonology particularly in the U.S. and Canada further supports market growth. According to the American Cancer Society (2022), approximately 343,040 digestive system cancer cases and 395,600 genital system cancer cases were estimated in the U.S., highlighting the urgent demand for accurate diagnostic tools in the region.
The Asia Pacific region is projected to witness the highest compound annual growth rate (CAGR) during the forecast period, driven by increasing healthcare expenditure, improving access to cancer treatment, and rising awareness of advanced diagnostic methods. A growing elderly population and the high prevalence of chronic diseases are contributing to the demand for minimally invasive diagnostic procedures, including EUS needles.
As reported by the National Institutes of Health, Asia has a notably high incidence of gastric cancer, primarily due to Helicobacter pylori infections, dietary factors, smoking, and alcohol consumption creating substantial growth opportunities for the regional market.
Emerging Trends
Adoption of Fine Needle Biopsy (FNB) over Fine Needle Aspiration (FNA)
The use of FNB needles has been increasing because they better preserve tissue architecture and yield higher diagnostic material compared with traditional FNA needles.
Innovative Needle Tip Designs
New fork tip and crown tip needles require fewer punctures to obtain sufficient specimens, reducing procedure time and patient discomfort.
Rotational Tip Mechanisms
Needles with rotating tips have emerged, allowing advanced penetration with less forward pressure while maintaining tissue yield, which can improve access in fibrotic lesions.
Gauge Diversification for Precision Sampling
A wider range of needle gauges (19G, 22G, 25G) is now routinely available, enabling clinicians to balance ease of penetration against coresample size based on lesion characteristics.
Demand for Higher Cell Counts in Personalized Medicine
As personalized therapies grow, there is increased demand for needles and techniques that maximize cell count and preserve microarchitecture to support genomic and molecular analyses.
Use Cases
Pancreatic Mass Diagnosis
EUS FNA was performed in 162 of 179 cases (91%) targeting pancreatic lesions, with an average of 2.6 needle passes per procedure to obtain diagnostic material.
Lymph Node Metastasis Detection
Both EUS FNB and EUS‑FNA have shown high sensitivity for detecting metastatic lymph nodes, supporting accurate staging in over 85% of cases.
Subepithelial Gastrointestinal Tumor Sampling
Tissue from mucosal or submucosal tumors in the stomach and esophagus has been reliably acquired, facilitating diagnosis in more than 80% of suspected cases.
Therapeutic Drainage and Injection
EUS guided needle access has been applied to drain pancreatic pseudocysts and to inject celiac plexus neurolytic agents, reducing pain scores by up to 60% in selected patient cohorts.
Prevention of Additional Testing
In 88% of procedures, EUS (with or without FNA) achieved diagnostic or therapeutic goals, eliminating the need for follow up imaging or surgical sampling.
Conclusion
The global Endoscopic Ultrasound (EUS) Needles market is poised for steady expansion, driven by technological innovation, rising cancer prevalence, and growing demand for minimally invasive diagnostics. Advancements in needle design, coupled with increasing adoption of fine-needle biopsy techniques, are enhancing diagnostic yield and procedural efficiency.
Hospitals remain the primary end users, supported by robust healthcare infrastructure in regions like North America. Meanwhile, Asia Pacific is expected to offer high growth potential due to its rising healthcare burden. With expanding clinical applications and integration into therapeutic practices, EUS needles are becoming essential tools in modern diagnostic and interventional endoscopy.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
